Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy

• Status: Completed
• Trial end date: 2015-04-01
• Target enrollment: 0
• Participant gender: All

Summary

That anti-TNF therapy and rituximab therapy are equally effective in treating patients with rheumatoid arthritis who meet the eligibility criteria for biologic therapy in the British Society for Rheumatology guidelines, and have not previously been exposed to biologic therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Glasgow
• Collaborators: Arthritis Research UK; NHS Borders; NHS Fife; NHS Grampian; NHS Lothian; NHS Tayside
• Treatments: Adalimumab; Etanercept; Rituximab

Criteria

Inclusion Criteria:

• Rheumatoid arthritis

• Eligible for biologic therapy according to BSR/NICE guidelines

Exclusion Criteria:

• Prior biologic therapy

• Contra-indication to anti-TNF therapy or rituximab